You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

9 Results
Guidelines and Advice
Guidelines and Advice
Status: Current
ID: PET 13
Jan 2015
Guidelines and Advice
Jan 2015
Guidelines and Advice
Status: Current
ID: 17-1
Version: 2
Mar 2015
Drug
Other Name(s): Lonsurf®
Nov 2024
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Nov 2024
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal, 
Small bowel and appendix
Intent: Palliative
Funding:
Exceptional Access Program
    trifluridine / tipiracil - In combination with bevacizumab for treatment of metastatic colorectal cancer, according to clinical criteria
New Drug Funding Program
    Bevacizumab (Biosimilar) - In Combination with Trifluridine and Tipiracil for Previously Treated Metastatic Colorectal Cancer
Nov 2024
Guidelines and Advice
Status: In-Review
ID: 19-4
May 2015